sanderus_1 schreef op 4 maart 2018 13:40:
De start fase 2 studie met MOR106 zal waarschijnlijk eerstdaags aangekondigd worden.5
Status:ONGOING
A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moderate to severe atopic dermatitis
Name or abbreviated title of the trial where available :IGUANA
Sponsor's protocol code number MOR106-CL-201
Number of subjects for this age range: 180
www.clinicaltrialsregister.eu/ctr-sea...